| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,860 |
17,926 |
$2.76M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,052 |
8,574 |
$2.07M |
| 0225U |
|
4,112 |
3,780 |
$1.40M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,749 |
2,526 |
$735K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
3,581 |
3,434 |
$558K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,543 |
4,198 |
$331K |
| 71045 |
Radiologic examination, chest; single view |
2,820 |
2,660 |
$223K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,278 |
1,228 |
$160K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,217 |
1,053 |
$119K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,215 |
2,852 |
$115K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,969 |
1,858 |
$107K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,876 |
3,710 |
$102K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,928 |
10,929 |
$99K |
| 70450 |
Computed tomography, head or brain; without contrast material |
251 |
239 |
$91K |
| 80053 |
Comprehensive metabolic panel |
9,302 |
8,583 |
$90K |
| 71046 |
Radiologic examination, chest; 2 views |
568 |
548 |
$60K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
928 |
855 |
$59K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,485 |
1,427 |
$58K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
498 |
491 |
$49K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
334 |
325 |
$47K |
| 29581 |
|
919 |
274 |
$38K |
| J3490 |
Unclassified drugs |
1,759 |
1,362 |
$30K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,158 |
1,128 |
$27K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
300 |
284 |
$26K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
252 |
211 |
$24K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
488 |
157 |
$20K |
| 84484 |
|
1,733 |
1,511 |
$18K |
| 81001 |
|
4,048 |
3,860 |
$16K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
470 |
102 |
$16K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
147 |
132 |
$10K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
807 |
774 |
$8K |
| 81025 |
|
708 |
675 |
$7K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
15 |
14 |
$7K |
| 83880 |
|
264 |
227 |
$7K |
| 83605 |
|
647 |
591 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
96 |
87 |
$6K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
78 |
70 |
$6K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
713 |
600 |
$6K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
88 |
69 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
1,670 |
1,557 |
$4K |
| 81003 |
|
1,531 |
1,458 |
$4K |
| 83735 |
|
576 |
545 |
$3K |
| 83690 |
|
426 |
400 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
108 |
103 |
$3K |
| 87430 |
|
222 |
212 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
307 |
290 |
$2K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
54 |
24 |
$2K |
| 87088 |
|
156 |
149 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
34 |
16 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
56 |
55 |
$1K |
| 74018 |
|
13 |
12 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
259 |
226 |
$943.69 |
| 80061 |
Lipid panel |
57 |
57 |
$930.26 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
25 |
25 |
$922.25 |
| 87070 |
|
87 |
87 |
$895.94 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
58 |
55 |
$814.66 |
| 82962 |
|
291 |
251 |
$727.16 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
56 |
56 |
$660.66 |
| 87081 |
|
100 |
97 |
$660.56 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
66 |
60 |
$580.12 |
| J2704 |
Injection, propofol, 10 mg |
62 |
58 |
$457.48 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
51 |
50 |
$302.94 |
| Q3014 |
Telehealth originating site facility fee |
46 |
41 |
$228.93 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
43 |
42 |
$214.56 |
| 86803 |
|
13 |
13 |
$213.48 |
| 87807 |
|
14 |
14 |
$185.64 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
12 |
12 |
$169.33 |
| 82077 |
|
13 |
12 |
$120.80 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
30 |
28 |
$91.06 |
| A4217 |
Sterile water/saline, 500 ml |
13 |
12 |
$38.50 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
189 |
157 |
$18.92 |
| 0100U |
|
46 |
41 |
$0.00 |